雌三醇3,17-二已酸酯 | 104202-96-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雌三醇3,17-二已酸酯
• 中文别名: [1,1'-联苯基]-3-羧酸,3'-氟-4'-甲基-
• 英文名称: estriol 3,17-dihexanoate
• 英文别名: 3,17β-dihexanoyloxy-1,3,5(10)-estratrien-16α-ol；[(8R,9S,13S,14S,16R,17R)-3-hexanoyloxy-16-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] hexanoate
• CAS: 104202-96-2
• 化学式: C₃₀H₄₄O₅
• 分子量: 484.676
• InChiKey: ZOVABFBGAYSQTL-AECPDVIXSA-N

物化性质

• 沸点：
  582.7±50.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
  申请人：Schering Aktiengesellschaft

  公开号：EP1358881A1

  公开（公告）日：2003-11-05

  The invention relates to the use of esters of estriol, for example, an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).

  本发明涉及雌三醇酯（例如雌三醇-3,17-二丙酸酯或雌三醇-3,17-二己酸酯）用于治疗自身免疫性疾病，如多发性硬化症（MS）。
• Pharmaceutical packaging for estriol therapy
  申请人：The Regents of the University of California

  公开号：US10369158B2

  公开（公告）日：2019-08-06

  This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

  本发明涉及用于治疗神经退行性疾病（如多发性硬化症）的新型包装药品，以及使用这些产品的方法。
• Methods of monitoring estriol therapy
  申请人：The Regents of the University of California

  公开号：US10406169B2

  公开（公告）日：2019-09-10

  Provided are methods for treating a neurodegenerative disease, such as multiple sclerosis, in a subject receiving a first estriol treatment regimen, comprising obtaining a measurement of the serum estriol concentration in the blood of the subject, and administering a second estriol treatment regimen to the subject if the serum estriol concentration is less than 6 ng/mL. The daily amount of estriol administered during the second estriol treatment regimen is preferably greater than the daily amount of estriol administered during the first estriol treatment regimen.

  本发明提供了用于治疗接受第一种雌三醇治疗方案的受试者的神经退行性疾病（如多发性硬化症）的方法，包括测量受试者血液中的血清雌三醇浓度，如果血清雌三醇浓度低于6纳克/毫升，则对受试者施用第二种雌三醇治疗方案。在第二种雌三醇治疗方案中，每天施用的雌三醇量最好大于第一种雌三醇治疗方案中每天施用的雌三醇量。
• Estrogen combination for treatment of multiple sclerosis
  申请人：The Regents of the University of California

  公开号：US10799512B2

  公开（公告）日：2020-10-13

  Provided are methods for treating multiple sclerosis using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

  本发明提供了使用雌激素连续疗法结合定期服用孕激素治疗多发性硬化症的方法。
• Estrogen therapy for brain gray matter atrophy and associated disability
  申请人：The Regents of the University of California

  公开号：US10821117B2

  公开（公告）日：2020-11-03

  Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent.

  本发明提供了单独使用雌激素或与另一种制剂联合使用雌激素来减缓、阻止和逆转某些神经退行性疾病（包括多发性硬化症）的灰质萎缩和残疾进展的方法。